Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

FASEB Journal

Volumn 20, Issue 3, 2006, Pages 419-425

  El Agnaf, Omar M A ^a   Salem, Sultan A ^b   Paleologou, Katerina E ^b   Curran, Martin D ^c   Gibson, Mark J ^c   Court, Jennifer A ^d,e   Schlossmacher, Michael G ^d,e   Allsop, David ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

syn fibrils; CSF; Lewy bodies; Oligomers; PD

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; OLIGOMER; BIOPOLYMER; HYBRID PROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OLIGOMERIZATION; PARKINSON DISEASE; PLASMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; CEREBROSPINAL FLUID; CHEMISTRY; GEL CHROMATOGRAPHY; MIDDLE AGED; PREDICTION AND FORECASTING;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; BIOPOLYMERS; CHROMATOGRAPHY, GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; RECOMBINANT FUSION PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 33645833848     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.03-1449com     Document Type: Article

References (34)

1. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32
2. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
3. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Gen. 18, 106-108
4. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., et al. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173
5. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841
6. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
7. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473
8. Cookson, M. R. (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52
9. Martin, F. L., Williamson, S. J., Paleologou, K. E., Allsop, D., and El-Agnaf, O. M. A. (2004) Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept. Lett. 11, 229-237
10. Schapira, A. H. V. (1999) Science, medicine, and the future Parkinson's disease. Br. Med. J. 318, 311-314
11. Lang, A. E., and Lozano, A. M. (1998) Parkinson's disease - first of two parts. N. Engl. J. Med. 339, 1130-1143
12. Lang, A. E., and Lozano, A. M. (1998) Parkinson's disease - second of two parts. N. Engl. J. Med. 339, 1144-1153
13. 53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70
14. El-Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., Curran, M. D., Court, J. A., Mann, D. M. A., Ikeda, S. I., et al. (2003) α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945-1947
15. Gibb, W. R., and Lees, A. J. (1988) The relevance of the Lewy body to the pathogenesis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745-752
16. El-Agnaf, O. M. A., Walsh, D. M., and Allsop, D. (2003) Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2, 461-462
17. El-Agnaf, O. M. A., Mahil, D. S., Patel, B. P., and Austen, B. A. (2000) Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 237, 1003-1007
18. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., and Selkoe, D. J. (2003) The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595
19. Silverberg, G. D., Mayo, M., Saul, T., Rubenstein, E., and McGuire, D. (2003) Alzheimer's disease, normal pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2, 506-511
20. DeMattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., and Holtzman, D. M. (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Aβ) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81, 229-236
21. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267
22. Li, Q. X., Campbell, B. C., McLean, C. A., Thyagarajan, D., Gai, W. P., Kapsa, R. M., Beyreuther, K., Masters, C. L., and Culvenor, J. G. (2002) Platelet α- and γ-synucleins in Parkinson's disease and normal control subjects. J. Alzheimers Dis. 4, 309-315
23. Pitschke, M., Prior, R., Haupt, M., and Riesner, D. (1998) Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat. Med. 4, 832-834
24. Bieschke, J., Giese, A., Schulz-Schaeffer, W., Zerr, I., Poser, S., Eigen, M., and Kretzschmar, H. (2000) Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc. Natl. Acad. Sci. USA 97, 5468-5473
25. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576
26. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., and Stefani, M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (London) 416, 507-511
27. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (London) 416, 535-539
28. El-Agnaf, O. M. A., Nagala, S., Patel, B. P., and Austen, B. M. (2001) Nonfibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J. Mol. Biol. 310, 157-168
29. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269
30. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 5618, 486-489
31. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (London) 418, 291
32. Miller, D. W., Hague, S. M., Clarimon, J., Baptista, M., Gwinn-Hardy, K., Cookson, M. R. and Singleton, A. B. (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835-1838
33. Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349
34. El-Agnaf, O. M. A., Paleologou, K. E., Greer, B., Abogrein, A. M., King, J. E., Salem, S. A., Fullwood, N. J., Benson, F. E., Hewitt, R., Ford, K. J., et al. (2004) A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18, 1315-1317